Thermo Fisher and Juno sign seven-year CAR-T tech deal

By Flora Southey

- Last updated on GMT

GettyImages/7activestudio
GettyImages/7activestudio

Related tags Thermo fisher Thermo fisher scientific Thermo electron

Juno Therapeutics will use Thermo Fisher Scientific’s Cell Therapy Systems (CTS) technology to develop CAR T therapies for cancer treatments.

The agreement will see Thermo Fisher supply Juno with CTS Dynabeads CD3/CD28 for seven years in a nonexclusive licensing deal.

Thermo Fisher said the magnetic beads – which it makes at its manufacturing facility in Vilnius, Lithuania – activate and expand T cells specially designed to identify and combat cancer cells in patients. 

“Thermo Fisher’s Dynabeads T cell expansion bead platform is already proven in commercial manufacturing, and is known for greater stability and scalability, which are critical requirements for CAR T manufacturers,” ​Thermo Fisher COO Mark Stevenson told us.

According to Stevenson, the firms have worked together since Juno was founded in 2013.

“Today’s announcement formalises the relationship to allow maximum collaboration to bring product to patients,” ​he said.

Financial details of the deal were not disclosed.

Thermo Fisher also supplies​ its CTS Dynabeads technology for CAR-T immunotherapies to Swiss firm Novartis.

The US Food and Drug Administration (FDA) approved​ Novartis’ CAR-T immunotherapy Kymriah (tisagenlecleucel) in August last year, making it the first commercially available CAR-T treatment in the US.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars